Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study.
Alzheimer disease
Harmonization
Neurodegeneration
Quantitation
Standardization
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
20
03
2023
accepted:
17
05
2023
medline:
7
8
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Tau positron emission tomography (PET) imaging is a recently developed non-invasive tool that can detect the density and extension of tau neurofibrillary tangles. Tau PET tracers have been validated to harmonize and accelerate their development and implementation in clinical practice. Whereas standard protocols including injected dose, uptake time, and duration have been determined for tau PET tracers, reconstruction parameters have not been standardized. The present study conducted phantom experiments based on tau pathology to standardize quantitative tau PET imaging parameters and optimize reconstruction conditions of PET scanners at four Japanese sites according to the results of phantom experiments. The activity of 4.0 and 2.0 kBq/mL for Hoffman 3D brain and cylindrical phantoms, respectively, was estimated from published studies of brain activity using [ Contrast and RC converged at ≥ 4 iterations, the error rates of RC for GM and WM were < 15% and 1%, respectively, and noise was < 10% in Gaussian filters of 2-4 mm in images acquired using the four scanners. Optimizing the reconstruction conditions for phantom tau PET images acquired by each scanner improved contrast and image noise. The phantom activity was comprehensive for first- and second-generation tau PET tracers. The mid-range activity that we determined could be applied to later tau PET tracers. We propose an analytical tau-specific VOI template based on tau pathophysiological changes in patients with AD to standardize tau PET imaging. Phantom images reconstructed under the optimized conditions for tau PET imaging achieved excellent image quality and quantitative accuracy.
Identifiants
pubmed: 37243882
doi: 10.1007/s12149-023-01847-8
pii: 10.1007/s12149-023-01847-8
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
494-503Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K16747
Informations de copyright
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, et al. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015;42(9):1459–68.
pubmed: 25952279
doi: 10.1007/s00259-015-3067-9
As A. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391–460.
doi: 10.1002/alz.12068
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
pubmed: 29653606
pmcid: 5958625
doi: 10.1016/j.jalz.2018.02.018
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404.
pubmed: 16906426
pmcid: 3906709
doi: 10.1007/s00401-006-0127-z
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
pubmed: 1759558
doi: 10.1007/BF00308809
Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247–58.
pubmed: 27323247
doi: 10.1002/ana.24711
Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110–9.
pubmed: 26505746
doi: 10.1002/ana.24546
Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain. 2018;141(1):271–87.
pubmed: 29228201
doi: 10.1093/brain/awx320
Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of Tau deposition in the aging human brain. Neuron. 2016;89(5):971–82.
pubmed: 26938442
pmcid: 4779187
doi: 10.1016/j.neuron.2016.01.028
Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand
pubmed: 26936940
doi: 10.1093/brain/aww023
Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–36.
pubmed: 29449700
doi: 10.1038/nrneurol.2018.9
Declercq L, Rombouts F, Koole M, Fierens K, Marien J, Langlois X, et al. Preclinical evaluation of
pubmed: 28232614
doi: 10.2967/jnumed.116.185199
Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al.
pubmed: 26541774
doi: 10.2967/jnumed.115.164848
Lu J, Bao W, Li M, Li L, Zhang Z, Alberts I, et al. Associations of [
pubmed: 32694971
pmcid: 7338611
doi: 10.3389/fnins.2020.00604
Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with
pubmed: 31712323
pmcid: 7262222
doi: 10.2967/jnumed.119.236224
Sanabria Bohorquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, et al. [
pubmed: 31254035
doi: 10.1007/s00259-019-04399-0
Shcherbinin S, Schwarz AJ, Joshi A, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer
pubmed: 27151986
doi: 10.2967/jnumed.115.170027
Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. First in-human PET study of 3 novel tau radiopharmaceuticals: [
doi: 10.2967/jnumed.118.209916
pubmed: 30291194
pmcid: 6278898
Wood H. Alzheimer disease: [11C]PBB3–a new PET ligand that identifies tau pathology in the brains of patients with AD. Nat Rev Neurol. 2013;9(11):599.
pubmed: 24145369
doi: 10.1038/nrneurol.2013.216
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112–34.
pubmed: 30635637
pmcid: 6756230
doi: 10.1038/s41380-018-0342-8
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.
pubmed: 27296779
pmcid: 4906968
doi: 10.1186/s40478-016-0315-6
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.
pubmed: 26344059
pmcid: 4900162
doi: 10.1002/ana.24517
Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces
pubmed: 28359327
pmcid: 5374697
doi: 10.1186/s13195-017-0253-y
Kimura Y, Endo H, Ichise M, Shimada H, Seki C, Ikoma Y, et al. A new method to quantify tau pathologies with
pubmed: 26969002
pmcid: 4788664
doi: 10.1186/s13550-016-0182-y
Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther. 2020;12(1):49.
pubmed: 32340618
pmcid: 7187531
doi: 10.1186/s13195-020-00612-7
Ikari Y, Akamatsu G, Nishio T, Ishii K, Ito K, Iwatsubo T, et al. Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. EJNMMI Phys. 2016;3(1):23.
pubmed: 27709546
pmcid: 5052249
doi: 10.1186/s40658-016-0159-y
Akamatsu G, Ikari Y, Nishio T, Nishida H, Ohnishi A, Aita K, et al. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging. Ann Nucl Med. 2016;30(1):18–28.
pubmed: 26337533
doi: 10.1007/s12149-015-1024-0
Wagatsuma K, Miwa K, Kamitaka Y, Koike E, Yamao T, Yoshii T, et al. Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [
pubmed: 35246870
doi: 10.1002/mp.15593
Mattay VS, Fotenos AF, Ganley CJ, Marzella L. Brain tau imaging: food and drug administration approval of
pubmed: 32753388
doi: 10.2967/jnumed.120.252254
Tian M, Civelek AC, Carrio I, Watanabe Y, Kang KW, Murakami K, et al. International consensus on the use of tau PET imaging agent
pubmed: 34978595
pmcid: 8803772
doi: 10.1007/s00259-021-05673-w
Weber CJ, Carrillo MC, Jagust W, Jack CR Jr, Shaw LM, Trojanowski JQ, et al. The worldwide Alzheimer’s disease neuroimaging initiative: ADNI-3 updates and global perspectives. Alzheimers Dement (N Y). 2021;7(1): e12226.
pubmed: 35005206
Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, et al. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2110–20.
pubmed: 33590274
pmcid: 8175320
doi: 10.1007/s00259-020-05156-4
Chiotis K, Dodich A, Boccardi M, Festari C, Drzezga A, Hansson O, et al. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2086–96.
pubmed: 33723628
pmcid: 8175292
doi: 10.1007/s00259-021-05277-4
Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, et al. Clinical validity of increased cortical uptake of [
pubmed: 33547556
pmcid: 8175307
doi: 10.1007/s00259-020-05118-w
Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, et al. Biodistribution and Radiation dosimetry for the tau tracer
pubmed: 28336780
doi: 10.2967/jnumed.116.189126
Koole M, Lohith TG, Valentine JL, Bennacef I, Declercq R, Reynders T, et al. Preclinical safety evaluation and human dosimetry of [
pubmed: 31111397
doi: 10.1007/s11307-019-01367-w
Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of tau load using [
pubmed: 28374171
pmcid: 5662681
doi: 10.1007/s11307-017-1080-z
Chen J, Li Y, Pirraglia E, Okamura N, Rusinek H, de Leon MJ, et al. Quantitative evaluation of tau PET tracers
pubmed: 29704038
pmcid: 6174003
doi: 10.1007/s00259-018-4040-1
He M, Baker SL, Shah VD, Lockhart SN, Jagust WJ. Scan-time corrections for 80–100-min standardizetd uptake volume ratios to measure the
pubmed: 30235119
doi: 10.1109/TMI.2018.2870441
Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [
pubmed: 27355840
pmcid: 4927104
doi: 10.1371/journal.pone.0158460
Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with
pubmed: 29880509
doi: 10.2967/jnumed.118.208215
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [
pubmed: 30326496
pmcid: 6233630
doi: 10.1001/jama.2018.12917
Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78(8):961–71.
pubmed: 34180956
pmcid: 8240013
doi: 10.1001/jamaneurol.2021.1858
Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [
pubmed: 30064520
pmcid: 6069775
doi: 10.1186/s13195-018-0402-y
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al.
pubmed: 32671408
doi: 10.1093/brain/awaa180
Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the national electrical manufacturers association NU 2–2001 standard. J Nucl Med. 2005;46(12):2083–91.
pubmed: 16330574
Rausch I, Cal-Gonzalez J, Dapra D, Gallowitsch HJ, Lind P, Beyer T, et al. Performance evaluation of the biograph mCT Flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys. 2015;2(1):26.
pubmed: 26501827
pmcid: 4883615
doi: 10.1186/s40658-015-0132-1
van Sluis J, de Jong J, Schaar J, Noordzij W, van Snick P, Dierckx R, et al. Performance characteristics of the digital biograph vision PET/CT system. J Nucl Med. 2019;60(7):1031–6.
pubmed: 30630944
doi: 10.2967/jnumed.118.215418
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.
pubmed: 29173917
doi: 10.1016/j.ejmp.2017.09.124
Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [
pubmed: 32338734
doi: 10.1001/jamaneurol.2020.0528
Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561–71.
pubmed: 31784374
pmcid: 7067654
doi: 10.1016/j.jalz.2019.09.079
Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-based prediction of longitudinal tau positron emission tomography in alzheimer disease. JAMA Neurol. 2022;79(2):149–58.
pubmed: 34928318
doi: 10.1001/jamaneurol.2021.4654
Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M, et al. Longitudinal
pubmed: 34515754
pmcid: 8677534
doi: 10.1093/brain/awab248
Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, et al. A multicenter comparison of [
pubmed: 34041562
pmcid: 8175317
doi: 10.1007/s00259-021-05401-4
Teng E, Manser PT, Sanabria Bohorquez S, Wildsmith KR, Pickthorn K, Baker SL, et al. Baseline [
pubmed: 34852837
pmcid: 8638526
doi: 10.1186/s13195-021-00937-x
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13(3):205–16.
pubmed: 27697430
doi: 10.1016/j.jalz.2016.08.005
Bun S, Moriguchi S, Tezuka T, Sato Y, Takahata K, Seki M, et al. Findings of
pubmed: 35843629
pmcid: 9773651
doi: 10.1002/npr2.12281
Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48(7):2245–58.
pubmed: 33215319
doi: 10.1007/s00259-020-05099-w
Dore V, Bohorquez SS, Leuzy A, Shimada H, Bullich S, Bourgeat P, et al. Towards a universal cortical tau sampling mask. Alzheimer’s Dement. 2021. https://doi.org/10.1002/alz.055816 .
doi: 10.1002/alz.055816
Dore V, Bullich S, Bohorquez SS, Leuzy A, Shimada H, Rowe C, et al. CenTauR
doi: 10.1002/alz.061177
Verwer EE, Golla SSV, Kaalep A, Lubberink M, van Velden FHP, Bettinardi V, et al. Harmonisation of PET/CT contrast recovery performance for brain studies. Eur J Nucl Med Mol Imaging. 2021;48(9):2856–70.
pubmed: 33517517
pmcid: 8263427
doi: 10.1007/s00259-021-05201-w
Hoffman EJCP, Guerrero TM, et al. Assessment of accuracy of PET utilizing a 3-D phantom to simulate the activity distribution of [
pubmed: 1997482
doi: 10.1038/jcbfm.1991.32